We studied the effect of a single intravenous dose of tobramycin on the rate of bacterial eradication from urine in 10 patients with bladder catheters. The catheter was replaced 4 to 6 h after the tobramycin dose. Pseudomonas aeruginosa was found in 7 of the 10 patients, while members of the family Enterobacteriaceae accounted for the remaining pathogens. The MIC for each bacterium was determined in both broth and urine. Tobramycin eradicated the bacteria from eight patients. Bacteriuria resolved in 21.8 18.0 h, and urine bactericidal activity persisted for 43.4 20.3 h after the dose of tobramycin. Most patients were recolonized by another bacterial species if use of Foley catheters was resumed on a continuous basis. Two patients required additional doses of tobramycin to eradicate the original pathogen. There were significant temporal relationships between the pharmacokinetics of tobramycin and the change in colony count of bacteria in urine.
Urinary tract infections occur frequently in hospitalized patients with indwelling urinary catheters (14) . A variety of approaches have been advocated for the management of such patients, including changing of the catheter and the administration of systemic antimicrobial agents for various lengths of time (3, 4, 7, 14, 17) . Tobramycin is bactericidal against the majority of gram-negative bacilli, which are the pathogens most frequently encountered in urinary tract infections (9, 14) . In addition, tobramycin exhibits a postantibiotic effect (PAE) against gram-negative bacilli, in which the bacteria remain inhibited for a substantial period of time following removal of tobramycin from the media in vitro (1, 2) .
The objectives of this study were (i) to determine the MICs and MBCs of tobramycin in urine against the isolated pathogens, (ii) to compare the relative activity of tobramycin in urine and broth, (iii) to determine the tobramycin concentration-time profile in serum and urine following a single dose of tobramycin, (iv) to assess the rate of bacterial eradication in urine following a single dose of tobramycin, and (v) to determine the presence of an in vivo PAE by measuring serial changes in bacterial colony counts in urine.
MATERIALS AND METHODS
Patients with short-term (less than 30 days) indwelling urinary catheters were eligible for participation in the study. Written informed consent was obtained from the patient or next of kin. Cultures of urine were aspirated from the port at the distal end of the indwelling catheter after the port surface was cleansed with an alcohol swab. In all patients, two or more consecutive cultures were positive for greater than 100,000 CFU of tobramycin-susceptible, gram-negative bacilli per ml within 48 h of entry into the study. Patients were specifically included when they were febrile, their urinalyses revealed numerous leukocytes, or culture of their urine grew Pseudomonas aeruginosa. Patients who were afflicted with pathogens other than P. aeruginosa but who met all the remaining criteria for entry into the study were also eligible for participation.
Patients were excluded from the study if they had a history of an allergic reaction to an aminoglycoside antibiotic, their estimated creatinine clearance was below 30 ml/min, they were granulocytopenic, they had received antimicrobial therapy within 72 h of evaluation, or had known renal calculi or other marked urinary tract pathology. Patients were also excluded if vital signs and physical examination revealed the development of the sepsis syndrome or septic shock or if blood cultures drawn within 96 h of the study were positive for the growth of any pathogen.
All subjects had a pretherapy history and physical examination. Baseline serum chemistry profiles, complete blood counts with differential, and urinalysis with microscopy were obtained for each subject. Laboratory studies were repeated at 2, 5, and 10 days postdose. The vital signs of all patients were monitored at least every 8 h during the study period.
Tobramycin sulfate (1.7 mg/kg of ideal body weight) was diluted in 50 ml of 5% glucose in water and infused over 30 min into a peripheral vein. Six hours after the dose, the indwelling urinary catheter was removed and replaced with a fresh catheter by using aseptic techniques. Serum for the tobramycin assay was collected at 1, 2, 4, 6, and 12 h after administration of the dose and was frozen until it was assayed.
Three 5.0-ml aliquots of urine were collected prior to administration of the dose; and then urine was collected every 2 h after the dose for 12 h, every 4 h for 60 h, and on the mornings of study days 4, 5, and 10. Identification and susceptibility testing of the pathogens were performed by using the automated MicroScan system. The aliquots for colony count determination were collected in polypropylene tubes containing sufficient cellulose phosphate to bind and inactivate the tobramycin, on the basis of results of pilot studies performed in our laboratory.
The potential for bacterial contamination during the handling of specimens was evaluated. Three empty polypropyl- ene tubes and three tubes containing nonsterilized cellulose phosphate were filled with sterile, filtered urine, capped, and shaken. One milliliter of urine from each tube was then spread onto separate blood agar plates. None of the tubes supported bacterial growth, showing that neither the handling of the tubes nor the cellulose phosphate introduced contaminating bacteria. Serial dilutions of the patients' urine were made in sterile normal saline, and pour plates were prepared with Endo agar. Colony counts between 15 and 300 per plate after 18 h of incubation at 37°C were considered valid.
Assay. Serum and urine tobramycin concentrations were determined separately by using the Abbott TDx Fluorescence Polarization assay system. Concentrations in serum were determined in the usual fashion. Concentrations in urine were calculated by using a freshly prepared standard curve for urine. A nonlinear curve-fitting program (PCNON-LIN) was used to generate the standard curve, and a computer program in BASIC was used to calculate the tobramycin concentration based on the net polarization value reported by the TDx system (12) .
Aliquots of the same specimens were used for urine inhibitory titer (UIT) and urine bactericidal titer (UBT) determinations. These methods of determination were developed in our laboratory. UITs and UBTs were determined by using the Abbott MS2 research system. Two milliliters of the patient's urine was pipetted into the first MS2 research cartridge well. The next 10 wells contained 1.0 ml of filtersterilized (pore size, 0.22 pLm; Sterivex-GS filters) urine. Serial 1:2 dilutions were made by pipetting 1.0 ml of urine into wells 2 through 10. Well 11 contained filtered, sterilized diluent urine without antibiotic. The final volume in each well prior to inoculation was 1.0 ml. The pathogen from each patient was inoculated into fresh Mueller-Hinton broth and incubated at 37°C for approximately 4 h until the growth turbidity exceeded 108 CFU/ml on the basis of McFarland standards. Dilutions of these suspensions were made into sterile normal saline to a final concentration of approximately 107 CFU/ml. A 50-p.l aliquot of this saline suspension containing approximately 5 x 105 CFU of the patient's pathogen was inoculated into each MS2 research cartridge well. Inoculation of antibiotic-free well 11 served as the positive growth control. The cartridges were then placed into the MS2 research system and incubated at 35°C for 18 h under constant mechanical shaking. MS2-generated growth curves, and visual inspection of each well provided endpoints. The UIT was defined as the greatest dilution of the patient's urine that exhibited no visible growth after 18 h of incubation at 35°C in the Abbott MS2 research system. Aliquots of 50 ,u of each dilution with no visible growth were plated onto MacConkey agar and incubated at 37°C for 18 h. The UBT was defined as the greatest dilution of the patient's urine that exhibited no growth on agar.
RESULTS
Eleven patients were enrolled in the study. One patient was subsequently removed from the study when one of the two prestudy urine cultures revealed less than 105 CFU of bacteria per ml. Demographic data for the 10 evaluable patients are given in Table 1 . There were seven female and three male patients. Eight patients were admitted to the neurological service for cerebral vascular accidents, one patient was admitted for surgical revision of an abdominal aortic aneurysm, and one patient had a fractured hip. Two patients had current urological disease. Patient 7 had moderate hypoesthesia of the bladder, while patient 9 required an indwelling catheter for relief of a lower urinary tract obstruction. No calculi or masses were discovered in this patient. No patient had a foreign body other than the catheter in the urinary tract. Two patients had recently experienced traumatic removal of an indwelling urinary catheter, and 8 of 10 patients had a history of fecal incontinence. All patients had pyuria (defined as >6 to 25 leukocytes per high-power field on microscopic examination of the urine) and 40% had hematuria (defined as >6 to 25 erythrocytes per high-power field on microscopic examination of the urine). The urine tested nitrite positive in 80% of our patients. The initial estimated creatinine clearance averaged 42.7 + 7.7 ml/min.
A one-compartment model was fit to the postdistribution plasma tobramycin concentration data for each patient by using PCNONLIN. Concentration in plasma data were unavailable for one patient because of unsuccessful attempts to gain vascular access after the dose of tobramycin was administered. The peak concentration of tobramycin in serum calculated from the regression line of serum concentration-versus-time averaged 7.0 + 2.8 mg/liter. On average, the serum tobramycin concentration at 6 h postdose, when the urinary catheter was changed, was 3.1 + 0.7 mg/liter, which was still in excess of the MIC for all the pathogens in our study. The mean half-life of tobramycin in plasma was 4.9 ± 1.6 h in this population. There were no apparent adverse reactions to the single dose of tobramycin, either clinically or in changes in laboratory test results, in any subject.
As shown in Table 2 , the average initial colony count was 3.4 x 108 CFU/ml, with a range of 1 x 105 to 3.2 x 109 CFU/ml. Of the 10 patients studied, a single organism was identified on multiple urine cultures in 9 patients. One patient was infected with both P. aeruginosa and Enterobacter cloacae. The pathogen(s) was eradicated from eight patients by the single dose of tobramycin. Their urine cultures became negative for bacteria at a mean of 22.0 ± 16.8 h postdose. A reduction in urine colony counts to <200 CFU/ml was demonstrated in all patients and occurred hours before complete eradication in most patients. In patients 5 and 9, colony counts declined to zero within 24 h after the dose of tobramycin, but the original pathogen regrew rapidly; one was P. aeruginosa and one was Escherichia coli. Six of the eight patients in whom eradication was achieved were eventually recolonized with another bacterial species during the study period, typically 3 to 5 days posttreatment. In all six patients, bladder catheterization was continued. Gram-positive organisms accounted for two-thirds of the recolonizations. Enterococcus faecalis emerged in the urine cultures of one patient within 12 h of dosing. This organism may have been present in small numbers and may have been undetected at the initiation of therapy. Alternatively, it may have been introduced into the bladder when the urinary catheter was replaced.
The maximum concentrations of tobramycin in urine occurred 2 to 4 h postdose and measured 256 ± 147 mg/liter. Figure 1 depicts the relationship between the mean colony count in urine (as the natural logarithm) and the mean tobramycin concentration in urine (as the natural logarithm) over time for the eight successfully treated patients. The mean tobramycin concentration in urine declined in a linear fashion, the regression line being described by the following: (ln urine tobramycin concentration) = -0.09 (time) + 5.05 (r2 = 0.93). Measurable tobramycin concentrations persisted long after colony counts fell to zero. It should also be noted that Fig. 1 shows that mean colony counts at 24 and 28 h postdose were higher than they were at 16 h postdose. This may be an artifact of the sampling schedule, since the sampling time changed from every 2 h to every 4 h during this interval. The surviving bacteria inside the catheter were thus given an additional 2 h to multiply prior to sampling. Alternative explanations may also exist.
The maximum UBT ranged from 1:4 to 1:512, with the median value being 1:16. Both the high and low values were seen with P. aeruginosa. Because urine tobramycin concentrations were measured, the urine inhibitory concentration (UIC) and the urine bactericidal concentration (UBC) corresponding to each UIT and UBT were determined, and the median UIC and UBC were calculated for each subject ( Table 2 ). In our group of patients, the mean UIC was 6.75 times higher than the mean MIC in broth, and the mean UBC was 12.63 times higher than the mean MIC in broth. Figure  2 depicts the relationship between the mean tobramycin concentration in urine and two measures of inhibitory activity for the eight successfully treated patients. The mean tobramycin concentration in urine greatly exceeded both the MIC and the UIC shortly after dosing. The superior activity of tobramycin in broth compared with that in urine is apparent, although the slopes of the lines were very similar. For broth determinations, the regression line is described by the following: (ln tobramycin concentrations/MIC) = -0.14 (time) + 7.65 (r2 = 0.93). For determinations in urine, the regression line is described by the following: (ln tobramycin concentration/UIC) = -0.14 (time) + 6.25 (r2 = 0.86). tially higher than the corresponding MICs determined in TIME (hours) broth (0.8 ± 0.5 mg/liter). The sevenfold difference is conInhibitory activity of tobramycin in urine over time. The sistent with the data given in a previous report (11) , in which io of tobramycin concentration in urine/MIC (0) and the decreased activity of aminoglycosides in urine was shown. io of tobramycin concentration in urine/UIC (0) are shown
The reduction in activity is the result of several factors, iatural logarithms.
including acidic pH, high osmolality, and the presence of cations such as calcium and magnesium (11) . Urine pH was determined three times daily for each of our subjects and for a mean of 43.4 ± 20.3 h after the tobramycin was typically slightly acidic (pH s6). The diluent urine used ie median duration was 48 h. The urine of all but one in testing was also pH 6, and the pH was shown to remain had bactericidal activity for over 24 h. In seven of the constant or rise slightly (0.5 pH units) during incubation with tients from whom the organism was eradicated, urine the pathogen. No attempt was made to standardize the pH idal activity persisted long after the urine cultures prior to testing, because it was the intent of the study to negative. Several patients, however, became recolmatch the in vivo situation. n 4 to 5 days ( Table 2 ).
The importance of achieving inhibitory or bactericidal activity in urine has been established (8, 10, 15, 16) . Bacte-DISCUSSION ricidal concentrations were achieved in the urine of all of our patients. Bacteriuria was not cleared in two subjects, howgle dose of tobramycin successfully eradicated the ever. These results support the conclusion of McCabe and pathogen(s) in 8 of 10 patients. Three of three male Jackson (10) that urine inhibitory activity is important but and five of seven female patients were successfully does not guarantee a successful bacteriological outcome. The success of the single-dose regimen in male
The two patients with treatment failure might have develsuggests that the prostate was not infected in these oped pyelonephritis, which is generally not responsive to This diagnosis, however, was not completely ruled single-dose therapy. Although neither patient exhibited flank )static massage was not performed on male patients pain, pyelonephritis was not ruled out by the use of invasive me of catheter change, when such a procedure might studies. en performed successfully. The contribution of cathBecause of the prolonged activity of tobramycin in the inge alone on bacterial counts was assessed. The urinary tract and the complete eradication of most of the counts obtained immediately following the catheter pathogens, we were not able to demonstrate an in vivo PAE were a mean of 77 ± 38% lower than those counts in these patients. In one patient, urine cultures remained d prior to the catheter change. Subsequent reducpositive 17 h beyond the last measurable UIC and UBC, colony counts could be attributable only to the after which time the cultures remained negative. Subinhib-)f the tobramycin. Rubin et al. (13) examined the itory concentrations of tobramycin were present in the fcatheter exchange without concomitant administrapatient's urine during this period. It is possible that this antimicrobial agents. In 93% of patients (25 of 27 represents an in vivo PAE. The significance of this finding is ), colony counts remained >i05. The larger decrease unclear because only one patient exhibited this phenomeour patients was most likely due to the presence of non. Future studies regarding an in vivo correlate to the PAE ycin in the urine. Exchange of the catheter alone did should use an agent with a shorter half-life in urine, to more ount for the elimination of bacteriuria.
closely mimic the "pulse exposure" used in vitro. BetaEand colleagues (5, 6) studied the kinetics of E. coli lactam antibiotics would be good candidates, although only Lion from urine following doses of beta-lactam antiimipenem has demonstrated an in vitro PAE. In addition, and trimethoprim-sulfamethoxazole. There was a strain identification of all cultured organisms would be useful cline in colony counts from midstream urine samples in distinguishing between recurrence of the original pathogen first 4 h following either ampicillin or trimethoprimand reinfection by another strain. thoxazole administration, but few urine specimens
In conclusion, a single dose of tobramycin was effective in -rile at 4 h. In contrast, cefotaxime eradicated all four eradicating the pathogen(s) in 8 of 10 patients and was well infections treated in the first 4 h. With the tested tolerated. Even though tobramycin was seven times less tam agents, bacteriuria was typically eradicated by active in urine than it was in broth, urine bactericidal activity manifest the signs and symptoms of infection which prompted the initial treatment. Therefore, a single dose of tobramycin, followed by a catheter change, effectively resolved the infectious process in most of our patients.
